12:58 PM EDT, 04/29/2024 (MT Newswires) -- Addex Therapeutics ( ADXN ) shares plunged 51% in recent Monday trading after the company said adjunctive administration of its investigational drug ADX71149 with levetiracetam or brivaracetam did not meet the primary goal of the phase 2 study.

ADX71149 included with standard treatment did not show any significant reduction in time for patients to reach baseline seizure count in the mid stage trial, the company added.

The study evaluated 50 milligrams and 100 milligrams doses of ADX71149 in 110 evaluable patients, who also received the standard dose of levetiracetam or brivaracetam and up to three other anti-seizure drugs, according to Addex.

Price: 7.84, Change: -8.26, Percent Change: -51.30